The Espinosa Neuroscience Institute - Dr. Patricio Espinosa MD MPH FAAN

On Monday, the FDA announced the historic fast-tracked approval of Biogen’s Aduhelm (aducanumab) for the treatment of Alzheimer’s disease. This is the first drug to target the pathophysiology of Alzheimer’s and significantly reduce amyloid beta plaque in patients.

There has not been an FDA-approved treatment for the disease since 2003, and we are tremendously delighted by this news.

Coming soon to MNI